SYS-CON MEDIA Authors: Jason Bloomberg, Eric Brown, Bob Gourley, Sandi Mappic, RealWire News Distribution

News Feed Item

Research and Development Forecast of China Heparin Industry, 2013-2017

NEW YORK, Jan. 21, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Research and Development Forecast of China Heparin Industry, 2013-2017
http://www.reportlinker.com/p01957801/Research-and-Development-Forecast-of-China-Heparin-Industry-2013-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Research_and_Development

Research and Development Forecast of China Heparin Industry, 2013-2017 mainly analyzes the global and domestic market status quo of heparin industry, development conditions of heparin upstream and downstream industry, the supply and demand of major products, competitive pattern and business performance of domestic major enterprises; in the meanwhile, it makes the analysis and forecast of the future development of the heparin industry, offering the decisive reference for enterprises to know and invest the heparin industry.

The global heparin API manufacturing enterprises are mainly concentrated in the China, Europe and the US; the supply volume of heparin APIs of these three regions accounts for more than 95% of the global supply volume; the supply volume of heparin AIPs in China ranks the world first and accounts for more than 50% of the global supply volume.

According to the statistics of China Customs, since 2007, the export amount of China's heparin products has been rising greatly for a fourth consecutive year; in 2011, under the affection of depressed international market and the improvement of heparin export standards, the export volume and amount of China's heparin products had the obvious decline; in the year of 2012 and 2013, the decline trend of the export volume of heparin products slowed, but the export amount still had a certain decline because of the price.

At present, China has totally 22 heparin API manufacturing enterprises that have passed the approval of China Food and Drug Administration, but there are less than 10 manufacturers that have engaged in the actual production; in addition, there are 500 to 1,000 companies of heparin crude products, which form the high domestic heparin API production concentration ratio; the production capacity is mainly concentrated in the top five manufacturing enterprises of heparin products with about 80% of market shares totally now. Hepalink has the largest market shares of about 40% in the domestic market; the other major enterprises include Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Changzhou Qianhong Bio-pharma Co., Ltd., Yantai Dongcheng Biochemicals Co., Ltd. and Qingdao Jiulong Biomedicine Co., Ltd., while the downstream resource are inadequate.
1. Industry Overview of Heparin
1.1 Definition and Classification
1.1.1 Definition
1.1.2 Classification
1.2 Industrial Chain

2. China's Heparin Industry Development Environment
2.1 China's Economic Development Environment
2.2 Related Policies and Standards
2.2.1 Related Policies and Regulations
2.2.2 Related Standards

3. Development Overview of China's Heparin API (Active Pharmaceutical Ingredient) Industry
3.1 Development Overview of Global Heparin Industry
3.2 Status Quo of China's Heparin API Industry
3.2.1 Market Status Quo
3.2.2 Market Supply and Demand
3.3 Imports and Exports
3.4 Competitive Pattern

4. Development Overview of China's Heparin Upstream and Downstream Industry
4.1 Upstream Industry
4.2 Downstream Industry
4.2.1 Low Molecule Weight (LMW) Heparin Preparations
4.2.2 Unfractionated Heparin Preparations

5. China's Major Heparin Manufacturing Enterprises
5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd. (Hepalink)
5.1.1 Company Profile
5.1.2 Business Performance
5.1.3 Research & Development and Investment
5.1.4 Development Prospects
5.2 Changzhou Qianhong Bio-pharma Co., Ltd.

5.2.1 Company Profile
5.2.2 Business Performance
5.2.3 Research & Development and Investment
5.2.4 Development Prospects
5.3 Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
5.3.1 Company Profile
5.3.2 Business Performance
5.3.3 Research & Development and Investment
5.3.4 Development Prospects
5.4 Yantai Dongcheng Biochemicals Co., Ltd.
5.4.1 Company Profile
5.4.2 Business Performance
5.4.3 Research & Development and Investment
5.4.4 Development Prospects
5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd.
5.5.1 Company Profile
5.5.2 Business Performance
5.5.3 Research & Development and Investment
5.5.4 Development Prospects
5.6 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
5.6.1 Company Profile
5.6.2 Research & Development
5.6.3 Development Prospects
5.7 Qingdao Jiulong Biomedicine Co., Ltd.

6. Investment Analysis of Heparin Industry
6.1 Investment Risks
6.1.1 Industry Risk
6.1.2 Intensifying Market Competition
6.1.3 Loss of Technical Personnel
6.1.4 Downward Product Price
6.1.5 Raw Material Price Fluctuation
6.1.6 Exchange Rate Fluctuation
6.2 Investment Suggestions
6.2.1 Investing the Scale Enterprises
6.2.2 Paying Attention to Brand Building
6.2.3 Doing Well Human Resource Management
6.2.4 Developing New Products and Being Diversified
6.2.5 Competition Alliance

7. Development Trends and Forecast of Heparin Industry
7.1 Development Trends
7.2 Market Scale Forecast of Heparin Products

To order this report: Research and Development Forecast of China Heparin Industry, 2013-2017
http://www.reportlinker.com/p01957801/Research-and-Development-Forecast-of-China-Heparin-Industry-2013-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Research_and_Development

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.